Antitumor effects of sulindac in ovarian cell cultures;Przeciwnowotworowy efekt sulindaku w hodowlach komórek raka jajnika

Ginekologia Polska

Volumn 82, Issue 3, 2011, Pages 195-199

  Anna, Jakubowska Mućka ^a   Jacek, Sieńko ^b   Tomasz, Świtaj ^a   Jakub, Gołab ^c   Witold, Lasek ^c  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Nonsteroidal anti inflammatory drugs; Ovarian cancer; Sulindac

Indexed keywords

EID: 79955422412     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Half E, Arber N. Colon cancer: preventive agents and the present status of chemoprevention. Expert Opin Pharmacother. 2009, 10, 211-219.
2. Sheehan K, Sheahan K, O'Donoghue D, [et al.]. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA. 1999, 282, 1254-1257.
3. Stelmaszuk T, Jałocha Ł, Wojtuń S, Gil J. Chemoprewencja raka jelita grubego. Pol Merk Lek. 2009, XXVI, 155, 565-568.
4. Cuzick J, Otto F, Baron J, [et al.]. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009, 10, 501-507.
5. Andrews P, Zhao X, Allen J, [et al.]. A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother Pharmacol. 2008, 61, 203-214.
6. Chen S-T, Thomas S, Gaffney K, [et al.]. Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2. Leukemia Res. 2010, 34, 250-253.
7. Bock J, Menon S, Goswami P, [et al.]. Differential activity of sulindac metabolites against squamous cell carcinoma of the head and neck is mediated by p21waf1/cip1 induction and cell cycle inhibition. Cancer Biol Ther. 2007, 6, 30-39.
8. Gubbels J, Claussen N, Kapur A, [et al.]. The detection, treatment, and biology of epithelial ovarian cancer. J Ovarian Res. 2010, 3, 8.
9. Nowak-Markwitz E. Pegylated liposomal doxorubicin in ovarian cancer treatment (in Polish). Ginekol Pol. 2009, 80, 615-619. Polish.
10. Rioux N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicilic acid and NS-398. Cancer Res. 1998, 58, 5354-5360.
11. Thompson H, Jiang C, Lu J, [et al.]. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res. 1997, 57, 267-271.
12. Loveridge C, MacDonald A, Thoms H, [et al.]. The proapoptotic effects of sulindac, sulindac sulfone and indomethacine are mediated by nucleolar translocation of the RelA(p65) subunit of NF-KappaB. Oncogene. 2008, 27, 2648-2655.
13. Gardner S, Hawcroft G, Hull M. Effect of nonsteroidal anti-inflammatory drugs on β-catenin protein levels and catenin-related transcription in human colorectal cancer cell. Br J Cancer. 2004, 91, 153-163.
14. Rodriguez-Burford C, Barnes M, Oelschlager D, [et al.]. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res. 2002, 8, 202-209.
15. Kim J-S, Baek S, Sali T, Eling T. The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15. Mol Cancer Ther. 2005, 4, 487-493.
16. Barnes A, Miller B, Kucera G. Cyclooxygenase inhibition and hyperthermia for the potentiation of the cytotoxic response in ovarian cancer cells. Gynecol Oncol. 2007, 104, 443-450.
17. Han A, Song Z, Tong C, [et al.]. Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol. 2008, 583, 26-31.
18. Yamamoto Y, Yin M-J, Lin K-M, [et al.]. Sulindac inhibition activation of the NF-kappaB pathway. J Biol Chem. 1999, 274, 27307-27314.
19. Scheper M, Nikitakis N, Sauk J. Survivin is a downstream target and effector of sulindacsensitive oncogenic Stat3 signalling in head and neck cancer. Int J Oral Maxillofac Surg. 2007, 36, 632-639.
20. Seo A-M, Hong S-W, Shin J-S, [et al.]. Sulindac induces apoptotic cell death in susceptible human breast cancer cells through, at least in part, inhibition of IKKbeta. Apoptosis. 2009, 14, 913-922.
21. O'Connor R, O'Leary M, Ballot J, [et al.]. A pahase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother Pharmacol. 2007, 59, 79-87.
22. Flis S, Spłuwiński J. Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide. Anticancer Res. 2009, 29, 435-442.
23. Uddin S, Ahmed M, Hussain A, [et al.]. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer. 2010, 126, 382-394.
24. Tsujii M, Kawano S, Tsuji S, [et al.]. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998, 93, 705-716.
25. http://www.clinicaltrials.gov/ct2/show/NCT00368927 (15 lipca 2010).
26. http://www.clinicaltrials.gov/ct2/show/NCT00062023 (15 lipca 2010).
27. http://www.clinicaltrials.gov/ct2/show/NCT00245024 (15 lipca 2010).
28. http://www.clinicaltrials.gov/ct2/show/NCT00039520 (15 lipca 2010).